Drug intelligence / Profile preview

protegrin-1

Development stage
Preclinical
Lead developer
University of California, Los Angeles
Modality
Antimicrobial Peptides → Native Peptides → Peptides
Administration
Oral, Intravenous, Topical, Intradermal, Intranasal
01

Overview

Protegrin-1 (PG-1) is a potent, cationic 18-amino acid antimicrobial peptide (AMP) belonging to the cathelicidin family, originally isolated from porcine leukocytes. It adopts a stable β-hairpin structure stabilized by two internal disulfide bonds. PG-1 exhibits broad-spectrum microbicidal activity against Gram-positive and Gram-negative bacteria (including multidrug-resistant strains like MRSA and *Acinetobacter baumannii*), fungi, and certain enveloped viruses. Its primary mechanism of action involves binding to and disrupting microbial cell membranes through pore formation, leading to rapid lysis and cell death. Beyond its direct microbicidal effects, PG-1 possesses immunomodulatory properties, including the ability to temper inflammatory responses by inhibiting the NF-κB and MAPK signaling pathways. It has also been investigated for its potential to inhibit the Dengue virus NS2B-NS3 serine protease and for its anticancer activity against tumors such as glioblastoma. Although highly effective, the clinical development of the natural PG-1 peptide has been hindered by its toxicity to mammalian cells, particularly its hemolytic activity, which has led to the development of synthetic analogs with improved safety profiles.

Other names
PG-1PG1PG 1Protegrin 1Protegrin1Protegrin-1

Beyond the preview

Go deeper on protegrin-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on protegrin-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call